Eli Lilly and Regeneron Selected for FDA PreCheck Pilot Program to Accelerate Drug Manufacturing Facility Reviews
The U.S. Food and Drug Administration (FDA) has selected Eli Lilly, Regeneron, and five other companies as the first participants in its PreCheck pilot program aimed at expediting regulatory reviews of new pharmaceutical manufacturing facilities. The initiative allows regulators to begin reviewing construction sites early, potentially saving up to 14 months for participating firms.
Topics: domestic production pharmaceutical manufacturing regulatory review